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Aim To analyze the 3-year outcomes of lower body mass 
index (BMI) (<35 kg/m2) adjustable gastric band (AGB) re-
cipients across multiple sites in the French health insur-
ance system.
Methods From prospectively collected data on a co-
hort of 517 morbidly obese Swedish Adjustable Gas-
tric Band® (SAGB) patients (Clinical Trials Web database, 
#NCT01183975), a retrospective analysis of a subgroup of 
29 low-BMI patients was conducted. Patients had a severe 
obesity-related comorbidity, had undergone a prior bariat-
ric procedure requiring reintervention, or had a maximum 
adult BMI≥40. Safety (mortality, adverse events) and ef-
fectiveness (BMI change, excess weight loss [EWL, %], to-
tal body weight loss [%TBWL], quality of life [QoL], and co-
morbidities) were evaluated.
Results Multiple surgical teams/sites enrolled patients 
and performed SAGB procedures between September 2, 
2007 and April 30, 2008. Of 29 low-BMI patients (mean age, 
41.3 ± 10.3 years), 89.7% were female, and obesity duration 
was 13.6 ± 7.3 years. Mean BMI was 31.5 ± 3.7; there were 
37 comorbidities in 15/29 patients. At 3-year follow-up, 
BMI was 29.4 ± 4.9 (mean change, -2.3 ± 6.2; P = 0.069); to-
tal cohort EWL, 7.3 ± 74.8%; TBWL, 6.2 ± 18.8%; BMI≥30 to 
<35 EWL, 38.8 ± 48.0%; there were 7 comorbidities in 15/29 
patients (P < 0.031). There were 20 adverse events in 13 pa-
tients (44.8%); SAGBs were retained in 25/29 (86.2%) at 3 
years.
Conclusions In a retrospective analysis of a subgroup 
of BMI<35 kg/m2 patients, some following a prior bariat-
ric procedure, SAGB was found to be safe and effective at 
3-year follow-up.
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For over 2 decades, since publication of the 1991 National 
Institutes of Health (NIH) consensus conference statement 
(1), the cutoff point for bariatric surgery has been morbid 
obesity (body mass index [BMI, kg/m2]≥40 or ≥35 with co-
morbidities), also termed class II obesity by the World Health 
Organization (WHO) (2). This demarcation of access to bar-
iatric surgery was based on the observation that an increase 
in BMI leads to an increase in the risk of comorbid illness and 
premature death. Yet, investigation of the potential value of 
bariatric surgery as a safe and effective treatment for over-
weight (BMI 25-<30) and obesity class I (BMI≥30 to <35) pa-
tients has been under way since the publication of the NIH 
statement. In 1992 and 1995 landmark studies (3,4), Pories et 
al theorized that bariatric procedures might be safe and as 
beneficial for weight loss and comorbidity reduction in non-
morbidly obese patients as it was in the morbidly obese (5). 
In the last half decade, the least-invasive, lowest-risk restric-
tive procedures, such as adjustable gastric banding (AGB), 
have been employed at the forefront of exploring surgical 
options for the <35 BMI patient.
Adjustable gastric banding comprised the vast majority, 
nearly 90%, of bariatric procedures performed in morbidly 
obese patients in France prior to 2008 (6). To assess the na-
tional social insurance-supported use of the Swedish Ad-
justable Gastric Band (SAGB) (7,8), the French government 
commissioned a prospective, 31-center, “real-life,” obser-
vation of SAGB safety and effectiveness in class II and III 
obese patients (9). Between September 2, 2007 and April 
30, 2008, patients were selected and underwent SAGB im-
plantation in rural and urban centers. SAGB weight-loss 
effectiveness analyzed on an intent-to-treat basis at the 
3-year study endpoint was comparable to that of AGB find-
ings summarized by global meta-analyses (10,11). Under 
the “real-world” SAGB study protocol requirement of con-
secutive recruitment and surgeon discretion, 29 patients 
(5.6% of 517) were included in the national SAGB study 
who presented with a BMI<35 and a severe obesity-related 
comorbidity, and/or had experienced a prior complicated 
bariatric surgery requiring revision, and/or had previously 
sustained a maximum adult BMI≥40. With the aim of con-
tributing safety and effectiveness findings to the growing 
<35 BMI evidence base, we report 3-year outcomes for the 
French low-BMI SAGB study group.
Methods
study protocol
During 2007, the French Health Technology Assessment 
Body (HAS) (12,13) requested that Ethicon Endo-Sur-
gery (Europe) GmbH sponsored and performed a country-
wide health insurance study to assess reimbursement of 
the SAGB product in France. The study was registered (Clin-
ical Trials Web database, #NCT01183975) (14) and a spon-
sor-developed protocol and case report form developed 
to direct implementation of HAS requirements and good 
clinical practices (GCPs) (ie, patient welfare in study design, 
ethical study conduct), defined by ISO EN 14155-1 and -2 
(15,16). Ethical approval and protocol approval were giv-
en by HAS, the Commission Nationale de l’Informatique et 
des Libertés, and the Comité Consultatif sur le Traitement 
de l’Information en matičre de Recherche dans le domaine 
de la Santé. Treatment payments were covered by national 
health insurance (13).
A contract research organization, Medextens SARL, Paris, 
France, and an independent monitoring committee con-
sisting of a non-participating bariatric surgeon, a pharma-
cologist, and a medical nutritionist supervised the study’s 
progress and prepared an interim report for review by HAS 
and the sponsor. Patients were required to provide written 
informed consent before surgery per Declaration of Hel-
sinki (17) and GCP guidelines.
design and setting
The prospective, multicenter, noncomparative study de-
sign aimed to facilitate observation and reporting of out-
comes in a morbidly obese study cohort, of which the 
current low-BMI cohort was a subgroup (9). Primary HAS 
objectives were to asses SAGB safety (mortality, adverse 
event [AE] occurrence) and clinical effectiveness (changes 
in weight loss, quality of life [QoL], comorbid illness) in var-
ied French hospital settings.
In order to incorporate “real-life” practice experiences 
across geographically diverse regions of France, surgeons 
were selected from academic, private, and public institu-
tions with differing bariatric surgery volumes. Per GCP 
standards, surgeons were required to undergo training in 
the protocol; selected surgeons recruited SAGB patients 
consecutively.
Inclusion criteria
Study eligibility for the primary trial was based on a recruit-
ment goal of >500 patients with <20% loss to follow-up 
after 3 years. General inclusion criteria stipulated patients 
with morbid obesity after failed medical treatment and 
no contraindications in accord with French (12), Europe-
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an (18), and American NIH bariatric surgery guidelines (1). 
French residents with a BMI<35 were permitted inclusion 
in the consecutive SAGB study enrollment if they had an 
adult maximum BMI≥40, and/or had a severe obesity-re-
lated comorbidity (thus, were receiving SAGB as a primary 
intervention in the current study [an “index SAGB”]), or if 
they required reintervention following a complicated prior 
bariatric procedure [a “PBP+SAGB”] (SAGB as a secondary 
intervention).
Variables
Safety variables analyzed for the low-BMI cohort were mor-
tality and frequency of AEs. Effectiveness variables were 
evaluated as change over 3 years in absolute weight (AW); 
BMI; excess body weight (EW); percentage EW loss (%EWL), 
ie, baseline AW – follow-up AW/EW, calculated by Miller’s 
formulas (19-23) for identifying ideal weight, correspond-
ing to the midpoint value of the medium-frame range on 
the Metropolitan Life Insurance Height and Weight Tables 
×100; and percentage total body weight loss (%TBWL), 
(ie, baseline AW – follow-up AW/baseline AW × 100) (24). 
Health-related QoL and changes in comorbid illness were 
also analyzed.
Quality of life instruments
The generic EuroQoL 5-Dimensions (EQ-5D), a psychomet-
ric instrument valued for its utility in calculating quality ad-
justed life years as well as the relative cost-effectiveness of 
obesity interventions, such as AGB (25), was used as a mea-
sure of QoL. The EQ-5D is a health-related QoL evaluation 
with 5 items and a visual analogue scale (EQ-VAS) (26-29) 
that provides a 5-dimensional profile: mobility, usual activi-
ties, self-care, anxiety/depression, and pain/discomfort. Di-
mensions are presented as 1 item with 3 response options: 
severe problems, some problems, and no problems. Item 
responses can be weighted normatively to derive a utility 
score (range -0.594 to 1, where 1 = ultimate health). A clini-
cally important difference has been identified at ≥0.07 on 
the EQ-5D scale (29). The EQ-VAS module is a single-item 
global QoL evaluation in which patients rate their current 
health (scale from 0 = worst imaginable to 100 = best imag-
inable) (30).
data collection
Protocol-prescribed safety and weight data collection and 
assessment measures were the only standardized require-
ments for the surgical centers, per the “real-life” observa-
tional study design. Baseline characteristics (eg, gender, 
age) were collected; weight, obesity-related comorbid 
disease, and QoL were recorded on the day of surgery, 
and at 1, 3, 6, 12, 18, 24, and 36 months postoperatively. 
Comorbidity data were sought via questionnaire; diagno-
ses were established and recorded consonant with indi-
vidual investigators’ typical practice via the password-pro-
tected Medextens-Medalliance eCRF Manager (v.1.3) web 
database.
For the current low-BMI subgroup study, data were re-
trieved from the original HAS archive and sorted by script 
for the known 29 target patients. Coded variables that ad-
dressed identified study topics were chosen and manually 
exported to a dedicated SPSS database.
technique
SAGB procedures were performed via pars flaccida tech-
nique (31), and band adjustments were accomplished at 
the discretion of the surgeons. Three SAGB model options 
were available: 2200-X Quick-Close; 2100-X (with locking 
ring and injection port); and the BD2XV Quick-Close with 
VelocityTM injection port.
statistical analysis
Statistical analyses were performed using the SPSS® soft-
ware package (ver. 20, IBM SPSS, Chicago, IL, USA). Quan-
titative demographic variables were generally reported as 
median and interquartile range (IQR); qualitative variables 
(demographic and outcome) were reported as number 
and percentage. Adverse events were also reported as 
number and percentage. Quantitative measures of change 
from baseline at 3 years were analyzed using the related-
samples Wilcoxon signed rank test; between-group com-
parisons were made with the Mann-Whitney U test. The 
Fisher exact test was used to investigate relationships be-
tween qualitative variables. Multivariate modeling, linear 
regression, and logistic regression were used to explore 
relationships between patient characteristics, weight loss, 
and QoL. Alpha was set at P < 0.05.
Results
Screening and enrollment of patients occurred between 
September 2, 2007 and April 30, 2008. The last follow-up 
visit at 3 years, due on April 30, 2011, was extended to 
November 20, 2011 to accommodate patients’ sched-
ules. All low-BMI cases were treated laparoscopical-
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ly using pars flaccida technique and port fixation with no 
conversions to laparotomy.
Baseline patient characteristics
The SAGB BMI<35 sample consisted of 89.7% (N = 26) fe-
male and 10.3% (N = 3) male patients with a median age of 
38.8 years, obesity duration of 12.0 years, AW of 87.0, EW of 
28.5, and median BMI of 33.1 (Table 1). Nine (31%) patients 
had a baseline BMI<30 and 20 (69%) had a BMI≥30 to <35.
Fifty-two percent (15/29) of patients presented with at 
least one comorbidity. Median EQ-5D was 0.7 and me-
dian VAS, 50.0. A history of family obesity was reported in 
19 patients (65.5%). SAGB was the first bariatric surgery 
in 12 patients (41.4%), referred to subsequently as index 
SAGB patients, and a reintervention following a prior bar-
iatric procedure that involved serious complications in 
17 (58.6% PGP+SAGB patients). Fifteen of 17 PBP+SAGB 
patients indicated that they had undergone prior AGB, 
while 1 reported prior sleeve gastrectomy, and 1, prior 
gastric balloon; 15/17 reported having had good results 
(ie, weight loss and comorbidity reduction) before expe-
riencing poor weight loss and a variety of complications 
and subsequently selecting SAGB as their reintervention 
treatment. This subjective reporting was corroborated 
by baseline data analysis that indicated that PBP+SAGB 
patients, compared to index SAGB patients, had a signifi-
cantly lower median (IQR) number of comorbidities (0.0 
[0.0-0.5] vs 2.0 [1.3-4.0]; P = 0.001), significantly higher 
global QoL [EQ-VAS] (70.0 [50.0-80.0] vs 40.0 [25.0-55.0]; 
P = 0.003), and significantly lower median BMI (30.1 [27.7-
33.2] vs 34.6 [34.0-34.8]; P = 0.002). Indeed, 8/9 BMI<30 
SAGB patients (89%) were PBP+SAGB patients; where-
as 45% (9/20) of BMI≥30 to <35 SAGB patients were 
PBP+SAGB patients. With respect to results and inter-
pretation presented herein, BMI<35 PBP+SAGB patients 
were, largely, former class-III (≥40 kg/m2) morbidly obese 
patients. Maximum adult BMI for PBP+SAGB patients was 
significantly greater than that for index SAGB patients 
(40.4 [38.1-42.6] vs 35.8 [34.2-37.5]; P = 0.001).
Adverse events
Fifty-five percent (16/29) of SAGB patients presenting with 
a BMI<35 experienced no adverse events (AEs) over 3-year 
follow-up. There was an 86.2% overall rate of band survival, 
that is, bands that remained implanted. There were 20 con-
firmed AEs in 13 patients (44.8%): 1 in 7 patients (24.1%); 
2 in 5 patients (17.2%); and 3 in 1 patient (3.5%). An over-
all rate of 0.23 confirmed adverse events per patient-year 
was observed. Confirmed AEs in order of frequency were: 
band removal 4 (14%), port rotation 3 (10.3%), band slip-
page 2 (7%), esophageal dilation 2 (7%), food intolerance 
2 (7%), abdominoplasty 2 (7%), dysphagia 1 (3.5%), GERD 
1 (3.5%), port malposition 1 (3.5%), port reintervention (no 
removal) 1 (3.5%), and port dysfunction/removal 1 (3.5%). 
PBP+SAGB patients had a significantly higher median 
number of AEs than index SAGB patients (1.0 [0.0-2.0] vs 
0.0 [0.0-0.0]; P = 0.030). In fact, 17/20 (85%) confirmed AEs, 
and all 4 confirmed band removals (ablations), occurred in 
the PBP+SAGB group. Conversely, 83.3% (10/12) of index-
SAGB patients experienced no AE.
Weight loss
Three-year postoperative weight outcomes for BMI<35 
SAGB patients were available in 86.2% (25/29) of patients. 
Median AW was 80.0 (72.0-88.0) compared to 87.0 (76.0-
tABle 1. Preoperative patient characteristics*
Characteristic Median (IQR), N = 29
Gender:
Male, N (%)  3 (10.3)
Female, N (%) 26 (89.7)
Age (yrs) 38.8 (33.9-50.4)
Duration of obesity (yrs) 12.0 (10.0-17.5)
Height (m)  1.7 (1.6-1.7)
AW (kg) 87.0 (76.0-94.5)
Ideal body weight (kg)† 60.9 (58.2-63.3)
EW (kg) 28.5 (16.3-33.0)
BMI (kg/m2): 33.1 (28.8-34.6)
<30, N (%)  9 (31.0)
≥30 and <35, N (%) 20 (69.0)
Intervention:
PBP + SAGB‡, N (%) 17 (58.6)
Index SAGB, N (%) 12 (41.4)
At least 1 comorbidity, N (%) 15 (51.7)
History of family obesity, N (%) 19 (65.5)
EQ-5D  0.7 (0.3-0.8)
EQ-VAS 50.0 (40.0-74.0)
*Abbreviations: IQR – interquartile range; BMI – body mass index; AW 
– absolute weight; eW – excess weight; PBP – Prior bariatric procedure 
before swedish Adjustable Gastric Band [sAGB] implantation in cur-
rent study; index sAGB – sAGB as first and only bariatric procedure; 
eQ-5d – euroQol 5-dimensions; eQ-VAs – euroQol-Visual Analogue 
scale.
†Ideal body weight derived from the Metropolitan Weight tables for 
life Insurance, 1983.
‡sAGB implant in this study was either an index intervention, or a 
sAGB following a complicated prior bariatric procedure (PBP) before 
the current study. 58.6% of the BMI<35 cohort were reintervention 
patients that satisfied the consecutive recruitment condition.
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94.5) at baseline (Table 2), representing a median AW re-
duction of 3.0 (-5.5-16.5: P = 0.126), corresponding to a 
median %TBWL of 2.9 (-6.6-17.5). Median EW was 22.1 
(10.0-26.9) compared to 28.5 (16.3-33.0) at baseline, repre-
senting a median EW reduction of 3.0 (-5.5-16.5: P = 0.126), 
corresponding to a median %EWL of 8.8 (-28.7-54.3). Me-
dian BMI was 30.1 (25.9-32.9), compared to a preoperative 
median BMI of 33.1 (28.8-34.6). This change represented 
an overall median BMI reduction of 1.0 (-2.0-6.0; P = 0.123). 
Median BMI evolution over 3 years by type of SAGB inter-
vention (PBP+SAGB vs index SAGB) for the BMI<35 cohort 
is presented in Figure 1.
Total cohort median changes in weight-related obesity indi-
cators were not significant at 3 years; however, a high level 
of individual variation in weight-loss outcomes was noted. 
While some BMI<35 patients lost significant weight, some 
gained weight as indicated by negative %TBWL and %EWL 
values. Subgroup analyses, by intervention type and BMI 
category, were carried out. As detailed in Table 2, index SAGB 
patients experienced significantly greater median %EWL 
than PBP+SAGB patients (51.1 [8.8-92.4] vs -20.0 [-68.8-18.6]; 
P = 0.001). In fact, while PBP+SAGB patients actually gained 
a median 4.0 kg of AW over 3 years, corresponding to a BMI 
increase of 1.6 kg/m2, index SAGB patients experienced sig-
tABle 2. Weight loss*†
Median (IQR), N = 25
total group Preoperative 3-y Median change P-value‡
AW (kg) 87.0 (76.0-94.5) 80.0 (72.0-88.0) 3.0 (-5.5-16.5) 0.126
BMI (kg/m2) 33.1 (28.8-34.6) 30.1 (25.9-32.9) 1.0 (-2.0-6.0) 0.123
EW (kg) 28.5 (16.3-33.0) 22.1 (10.0-26.9) 3.0 (-5.5-16.5) 0.126
TBWL (%) — 2.9 (-6.6-17.5) — —
EWL (%) — 8.8 (-28.7-54.3) —
subgroup 1 comparison
PBP+sAGB (n = 14)
AW (kg) 82.0 (74.5-89.3) 85.0 (78.0-90.8) -4.0 (-9.3-5.8) 0.401
BMI (kg/m2) 31.0 (28.0-33.1) 31.6 (29.0-33.3) -1.6 (-3.2-2.0) 0.421
EW (kg) 22.6 (13.5-29.3) 24.6 (17.6-28.6) -4.0 (-9.3-5.8) 0.401
TBWL (%) — -5.0 (-12.5-6.1) — —
EWL (%) — -20.0 (-68.8-18.6) — —
Index sAGB (n = 11)
AW (kg) 93.0 (87.0-100.0) 76.0 (65.0-83.0) 16.0 (3.0-31.0) 0.010
BMI (kg/m2) 34.5 (34.0-34.8) 28.5 (23.0-32.9) 5.9 (1.0-11.0) 0.010
EW (kg) 32.1 (29.4-34.1) 15.3 (2.5-22.1) 16.0 (3.0-31.0) 0.010
TBWL (%) — 17.0 (2.9-32.3) — —
EWL (%) — 51.1 (8.8-92.4) — —
subgroup 2 comparison
BMI<30 (n = 7)
AW (kg) 76.0 (68.0-85.0) 85.0 (80.0-88.0) -9.0 (-15.0 to -4.0) 0.042
BMI (kg/m2) 26.9 (25.7-28.7) 30.1 (27.4-33.4) -3.2 (-5.0 to -1.7) 0.042
EW (kg) 13.5 (13.1-15.9) 22.5 (15.9-33.1) -9.0 (-15.0 to -4.0) 0.042
TBWL (%) — -11.8 (-17.6 to -5.9) — —
EWL (%) — -66.5 (-153.3 to -28.3) — —
BMI≥30 (n = 18)
AW (kg) 90.0 (85.3-97.0) 78.0 (67.3-90.8) 10.5 (-0.5-19.8) 0.006
BMI (kg/m2) 34.0 (32.3-34.6) 29.6 (25.3-32.9) 3.7 (-0.2-7.6) 0.006
EW (kg) 31.1 (25.8-33.7) 20.0 (7.1-26.8) 10.5 (-0.5-19.8) 0.006
TBWL (%) — 11.0 (-0.7-23.0) — —
EWL (%) — 33.1 (-2.5-73.8) — —
*Abbreviations: IQR – interquartile range; BMI – body mass index; AW – absolute weight; eW – excess weight; PBP – Prior bariatric procedure before 
swedish Adjustable Gastric Band [sAGB] implantation in current study; eWl – eW loss; tBWl – total body weight loss.
†Calculations based on patients with complete preoperative and 3-y follow-up data.
‡Related samples Wilcoxon signed Rank test.
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nificant changes over time in median weight-loss indica-
tors: AW decreased by 16 kg (P = 0.010), corresponding to a 
BMI decrease of 5.9 kg/m2 (P = 0.010). Finally, patients with 
a baseline BMI≥30 to <35 had significantly greater median 
%EWL at 3 years than did those with a BMI<30 (33.1 [-2.5-
73.8] vs -66.5 [-153.3 to -28.3]; P = 0.001). The BMI≥30 to <35 
patient subset was further subdivided into PBP+SAGB (N = 8) 
vs index SAGB patients (N = 10). Figure 2 depicts the evolu-
tion of %TBWL and %EWL for BMI≥30 to <35 patients as 
moderated by whether they were a reintervention or index 
SAGB. PBP+SAGB patients experienced somewhat irregular 
median weight outcomes over time; whereas, index SAGB 
patients exhibited progressive, sustained weight loss: At 3 
years, PBP+SAGB median BMI was reduced by 1.3 (-1.1-4.7, 
P = 0.030), median %TBWL was 3.9 (-3.1-14.8), median %EWL 
was 11.8 (-8.8-49.0); index SAGB median BMI was significant-
ly reduced by 6.1 (0.5-12.1, P = 0.001), median %TBWL was 
17.4 (1.5-35.4), median %EWL was 51.0 (4.1-100.4).
In the development of a multivariate regression model 
exploring preoperative clinical variables significantly re-
lated to %TBWL (ie, presence of comorbidity [r = 0.493, 
P = 0.012], QoL [EQ-VAS] [r = -0.482, P = 0.027], type of SAGB 
operation (prior bariatric procedure or index SAGB proce-
dure) [r = 0.591, P = 0.002], and BMI [r = 0.631, P = 0.001]), 
only baseline BMI was found to be an independent predic-
tor of 3-year %TBWL in the BMI<35 SAGB cohort. Results 
of simple linear regression of %TBWL on baseline BMI in 
the form of a scatterplot and regression line are presented 
in Figure 3. Baseline BMI and 3-year %TBWL correlated at 
FIGuRe 1. evolution in median body mass index (BMI, kg/m2) 
over 3 years in swedish Adjustable Gastric Band (sAGB) cohort 
with baseline BMI<35 as moderated by intervention type 
(prior bariatric procedure [PBP+sAGB] vs first intervention [in-
dex sAGB]). error bars represent the ~ 95% confidence interval 
bracketing the median.
FIGuRe 2. Median weight-loss trends to 3 years post swedish 
Adjustable Gastric Band (sAGB) procedure for patients with 
preoperative body mass index (BMI, kg/m2)≥30 to <35 as 
moderated by type of operation (prior bariatric procedure 
[PBP+sAGB] vs first intervention [index sAGB]) expressed in 
percentage total body weight loss (%tBWl) and percentage 
excess weight loss (%eWl). Note: Follow-up rate at 18 and 24 
months was not sufficient for reliable assessment.
FIGuRe 3. scatter plot and regression line illustrating direct 
relationship between preoperative body mass index (BMI, 
kg/m2) and percentage total body weight loss (%tBWl) for 
BMI<35 patients following swedish Adjustable Gastric Band 
(sAGB) procedure at 3 years. Intersecting reference lines 
represent the point on the BMI axis (BMI = 30) above which a 
positive %tBWl is predicted to occur at 3-year sAGB follow-up.
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r = 0.631 (P = 0.001). A logistic regression model using BMI 
as the lone predictor was shown to correctly classify 83.3% 
of patients into their respective “weight-loss” vs “weight-
gain” groups. Logistic results are presented in the form of 
a probability curve in Figure 4 (BMI odds ratio = 1.53 [95% 
CI: 1.1, 2.2]; beta coefficient = 0.428, P = 0.048; model con-
stant = -13.2, P = 0.008).
Overall, 56.0% (14/25) of the SAGB BMI<35 cohort with 
complete weight data at 3 years achieved and main-
tained weight loss. Ninety-three percent (13/14) of those 
comprising the weight-loss group were patients who pre-
sented with a BMI≥30 to <35, and 57.0% (8/14) were index 
SAGB patients with a baseline BMI≥30 to <35. This subset 
of patients was the most successful in terms of weight loss: 
median baseline BMI was 34.7 (34.1-34.8) at 3-year follow-
up, median BMI fell significantly (7.7) to 26.7 (20.2-29.4; 
P = 0.001); %TBWL was 22.3 (15.2-41.7); %EWL was 64.5 
(44.4-116.3).
Comorbidities
Adhering to the study’s observational design, no diagnos-
tic tests for comorbidity assessment were required. At each 
visit, comorbidities were reported as present or absent. Sig-
nificant variation in diagnostic methodology, terminology, 
and reporting regularity was noted. Despite this limitation, 
qualitative analysis indicated a continued reduction in the 
overall number of comorbidities over time and a gradu-
al increase in those with no reported comorbidities. At 
baseline, there were 37 comorbidities in 15/29 BMI<35 pa-
tients. At 3-year follow-up, comorbidities were significantly 
reduced to 7 (P = 0.031); median number of comorbidities 
per patient fell significantly from 1.0 (0.0-2.0) at baseline to 
0.0 (0.0-0.0), P = 0.002.
Quality of life
Three-year postoperative QoL outcomes were available in 
58.6% of patients (17/29). Median EQ-5D utility score was 
0.8 (0.7-1.0) compared to 0.7 (0.3-0.8) at baseline (Table 3). 
This represented a significant within-patient median QoL 
improvement of 0.2 (0.0-0.3) (P = 0.028), greater than 2.5 
times the accepted clinically important difference. Median 
EQ-VAS was 75.0 (55.0-90.0) compared to 50.0 (40.0-73.8) 
at baseline; the median increase of 5.0 (-15.0-40.0) was 
not significant (P = 0.214). Regression analysis indicated a 
significant association between weight loss and QoL im-
provement. Using EQ-5D individual change scores as the 
response variable while controlling for baseline BMI, BMI 
reduction was significantly related to increasing EQ-5D 
utility scores (adjusted R2 = 0.30; F(2,13) = 4.3; P = 0.037).
dIsCussIoN
Results suggest that the SAGB was safe and effective in 
French patients with a baseline BMI<35. There was no mor-
tality and the AE rate was 0.23 AEs per patient-year, approx-
imately similar to the 0.19 AE rate found in the main HAS 
cohort study. Adverse events were primarily confined to 
PBP+SAGB patients; whereas, 83.3% of index SAGB pa-
tients experienced no AE. SAGB device survival rate 
was also comparable to that found in the main co-






EQ-5D  0.7 (0.3-0.8)  0.8 (0.7-1.0) 0.2 (0.0-0.3) 0.028
EQ-VAS 50.0 (40.0-73.8) 75.0 (55.0-90.0) 5.0 (-15.0-40.0) 0.214
*Abbreviations: Qol – Quality of life; eQ-5d – euroQol 5-dimensions; 
eQ-VAs – euroQol-Visual Analogue scale; IQR – interquartile range.
†P-values obtained from related-samples Wilcoxon signed Rank tests 
assessing median Qol differences in patients with complete preop-
erative and 3-y follow-up data (ie, N = 16 for eQ-5d, N = 17 for eQ-VAs).
FIGuRe 4. Probability curve depicting the likelihood of a 
patient with a given preoperative body mass index (BMI, kg/
m2) to experience weight loss (ie, positive percentage total 
body weight loss, %tBWl) at 3 years after swedish Adjustable 
Gastric Band (sAGB) procedure. Intersecting reference lines 
represent 3 sample patients with baseline BMIs of 30.0, 31.0, 
and 34.9 whose corresponding probability of weight loss at 3 
years following sAGB procedure are calculated to be 0.40, 0.50, 
and 0.86, respectively.
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hort study (86.2% vs 87.0%). QoL was improved and a re-
duction in overall number of comorbidities was observed. 
BMI reduction was significantly related to positive changes 
in patient health status. On balance, weight loss trended 
toward significance at 3 years; however, some patients 
demonstrated weight gain. For example, those present-
ing with a BMI<30 (89.0% PBP+SAGB) experienced a me-
dian 9.0-kg AW gain (TBWL = -11.8%). Conversely, patients 
with BMI≥30 to <35 experienced significant AW loss (10.5 
kg), median 33.1% EWL, and median 11.0% TBWL – more 
than double the 5.0% TBWL threshold associated with sig-
nificant comorbidity improvement (32). First-intervention 
BMI≥30 to <35 patients experienced a median EWL of 
51.0% (TBWL = 17.4%). In addition, within the BMI<35 co-
hort, logistic regression modeling suggested that a base-
line BMI≥30 was the point above which weight loss was 
likely to occur 3 years post SAGB surgery.
Although weight-loss findings for the BMI≥30 to <35 first-
time SAGB patients derive from a very small subgroup 
(N = 10), their median weight-loss outcomes over 3 years 
were comparable to those of the 517 morbidly obese pa-
tients of the original HAS cohort (median BMI change, 6.1 
vs 7.9; EWL, 51.0% vs 49.3%). The subgroup outcomes sug-
gest that surgical weight loss in patients in the BMI≥30 to 
<35 category follows a pattern similar to that in patients 
with BMI>35. The observation lends support to the idea 
that lowering the 1991 NIH (1) bariatric surgery cutoff to 
30 may be reasonable. In addition, obesity-related health 
risks, such as type 2 diabetes mellitus and cardiovascular 
disease, tend to arise at lower BMIs in certain non-Cauca-
sian populations (eg, Asian Indians) due to a higher per-
centage and central distribution of body fat (33-35). The 
Asian Indian Consensus Group, for example, has moved 
to evaluate weight-related health risk with alternatives to 
the BMI metric in these patients and to lower the BMI cut-
off for bariatric surgery to BMI>32.5 with a comorbidity or 
BMI>37.5 without comorbidities (36).
The American Society for Metabolic and Bariatric Surgery 
(ASMBS) Position Statement on BMI 30-35 concluded in late 
2012 that class 1 obesity leads to other serious comorbid 
illnesses and a lowered life expectancy, and that there was 
no evidence of clinical or cost-effectiveness, ethics, or eq-
uity that should exclude the BMI 30-35 group from bariat-
ric surgical treatment (37). The Statement recommended 
that, at a minimum, certain procedures (ie, gastric band-
ing, sleeve gastrectomy, Roux-en-Y gastric bypass [RYGB]) 
that have been shown safe and effective in short and 
mid-term randomized controlled trials in BMI 30-35 
patients should be an option for carefully selected patients. 
O’Brien et al (2006), for example, published a randomized 
controlled trial of AGB vs medical therapy in BMI 30-35 pa-
tients (2 groups of 40 patients each) that demonstrated 
equivalent weight loss at 6 months; at 2 years, the medical 
therapy group had regained most of their weight, whereas, 
the surgical group had an 87.2% EWL (-20 kg) (38). Also, the 
recently reported randomized controlled “Surgical Therapy 
and Medications Potentially Eradicate Diabetes Efficiently” 
(STAMPEDE) trial (2012) showed the effectiveness of sleeve 
gastrectomy and RYGB in BMI≥27 patients in reducing 
weight and treating type 2 diabetes mellitus (39).
Evidence for lowering the BMI cutoff for surgery comes 
from multiple observational studies as well, particularly 
with respect to the AGB procedure. Angrisani et al (2004) 
reported the Italian experience in 210 AGB patients with 
a mean preoperative BMI of 33.9. At 60-month follow-up, 
mean BMI was 29.2 (40). Parikh et al (2006) described a 26-
kg weight loss at 2 years in low-BMI AGB patients that was 
sustained at 3-year follow-up (41). In 2009, Sultan et al re-
ported 53 AGB patients with a mean baseline BMI of 33.1 
who attained a BMI of 25.8 and EWL of 69.7% at 2 years 
along with substantial improvement in comorbidities (42). 
Both Choi et al (2010) and Varela et al (2011) compared 
low-BMI and morbidly obese cohorts undergoing AGB 
and found the procedure comparably safe and effective 
in both weight categories (43,44); Varela et al also noted 
that low-BMI patients had shorter operative times and less 
blood loss.
In the current SAGB study, in which median weight loss 
in the BMI≥30 to <35 subgroup was significantly greater 
than in the BMI<30 subgroup, neither group lost an exces-
sive amount of weight; in fact, mean AW increased slightly 
in the BMI<30 group (mostly prior bariatric procedure pa-
tients), as is typical for bariatric surgery patients after the 
point of their greatest weight loss. In 2007, Scopinaro et al 
found in their study of low-BMI biliopancreatic diversion 
(BPD) patients that, although the mildly obese group lost 
nearly twice the weight of the overweight group, weight 
loss was not excessive in either low-BMI category (45). Oth-
er surgical studies, including those using BPD, BPD with 
duodenal switch, AGB, sleeve gastrectomy, and RYGB, have 
observed the same phenomenon (46-48). Weight loss ap-
pears to stabilize within the postoperative year at a BMI>25 
regardless of whether the procedure falls into the restric-
tive, malabsorptive/restrictive, or primarily malabsorptive 
surgical category (49), and regardless of the preoperative 
BMI. A homeostatic mechanism may exist that facilitates 
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weight loss in proportion to procedure-specific caloric 
absorption capacity (5). An integrative analysis of the 16 
then-existing bariatric surgery studies in low-BMI patients 
detected the same pattern of lesser weight loss in patients 
with BMI<30 than in those with a BMI≥30, suggesting a 
blunting of the weight-loss cascade at around 30 BMI.
Although the current study was limited by a restricted 
population of 29, the findings represent a small addition to 
the evidence base for bariatric surgery in the BMI<35 pa-
tients. As in results for the primary HAS “real-world” cohort 
study, the current low-BMI report contains an underreport-
ing bias partially due to data recording by numerous surgi-
cal teams across diverse locations in France; calculating a 
quantitative measure of change in specific comorbidities 
was, therefore, not possible.
As early as 1997, Mason et al noted the dramatic trend to-
ward increasingly higher weights in bariatric surgery can-
didates. They hypothesized that escalating obesity and 
life-threatening comorbidities should be prevented rather 
than treated in their full expression (50). Current study out-
comes and those of a growing evidence base appear to 
support the value of lowering the BMI access point for bar-
iatric surgery to permit earlier intervention in appropriate 
patients. Similar to findings in morbidly obese SAGB pa-
tients at 3 years, SAGB treatment for low-BMI patients in 
France, particularly those with BMI≥30 to <35, was found 
safe and effective.
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